Guenther Gastl

Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation.

Low concentrations of STI571 in the cerebrospinal fluid: a case report.

Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia.

Increase of regulatory T cells in the peripheral blood of cancer patients.

Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab.

Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival.

Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.

High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer.

CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice.

Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine.

Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions.

RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines.

Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.

The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation.

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients.

Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue.

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis.

Synergistic and additive antiproliferative effects on human leukemia cell lines induced by combining acetylenehexacarbonyldicobalt complexes with the tyrosine kinase inhibitor imatinib.

The effect of zoledronic acid on the function and differentiation of myeloid cells.

EpCAM expression in squamous cell carcinoma of the oral cavity: frequency and relationship to clinicopathologic features.

Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor.

STAT1 activation in squamous cell cancer of the oral cavity: a potential predictive marker of response to adjuvant chemotherapy.

Knockdown of PgP resensitizes leukemic cells to proteasome inhibitors.

Role of forkhead box protein 3 expression in invasive breast cancer.

Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions.

TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity.

Possible role for gene expression profiling in predicting responses to conventional or targeted drugs in patients with chronic myeloid leukemia.

Hodgkin lymphoma in Tyrol-a population-based study.

The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo.

GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib.

High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.

Effects of EpCAM overexpression on human breast cancer cell lines.

Clinical aspects, diagnostic challenges and management of patients with neuroendocrine tumors (NETs).

EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis.

High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trial.

Low expression of junctional adhesion molecule A is associated with metastasis and poor survival in pancreatic cancer.

Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.

EpCAM overexpression prolongs proliferative capacity of primary human breast epithelial cells and supports hyperplastic growth.

Transition of idiopathic CD4 + lymphocytopenia into mycosis fungoides?

Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancer.

Medical decision analysis for first-line therapy of chronic myeloid leukemia.

Systematic assessment of decision-analytic models for chronic myeloid leukemia.

Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas.

(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT.

The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics.

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.

Marine compounds inhibit growth of multiple myeloma in vitro and in vivo.

Treg(s) in Cancer: Friends or Foe?

Soluble EpCAM levels in ascites correlate with positive cytology and neutralize catumaxomab activity in vitro.

Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.

Detection of soluble EpCAM (sEpCAM) in malignant ascites predicts poor overall survival in patients treated with catumaxomab.

Oncotyrol--Center for Personalized Cancer Medicine: Methods and Applications of Health Technology Assessment and Outcomes Research.

Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancer.

High prevalence of side population in human cancer cell lines.

Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option.

Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.